ClinicalTrials.gg
Not yet recruitingNCT07945314Updated Nov 18, 2026

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy Participants

A Phase 1 interventional study of LY3839056 IV and Placebo IV in Healthy Participants, sponsored by Eli Lilly and Company. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to see if LY3839056 is safe and well tolerated when given as a single dose into a vein intravenous (IV) or under the skin subcutaneous (SC) in healthy participants. The study will also measure how much LY3839056 gets into the blood and how long it takes the body to remove it. The study will last up to 17 weeks and includes a stay of about 6 days at the clinical research unit.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and Cardiac Monitoring.
  • Have clinical laboratory test results within normal reference range for the population or the clinical research site, or results with acceptable deviations that are judged to be not by the investigator.
  • Have venous access sufficient to allow for IV drug delivery and blood sampling as per the protocol.
  • Have a within the range of 18.0 to 32.0 kg/m².
  • Participants assigned male or female at birth, including individuals of (IOCBP), may participate in this trial.
  • use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Key Exclusion Criteria:

  • Are or have a history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection.
  • Have a history or presence of cardiovascular, respiratory, hepatic, ophthalmological, renal, gastrointestinal, endocrine, hematological, neurological, or psychiatric disorders.
  • Had any surgical procedure (except for minor surgery requiring local or no anesthesia and without any complications or sequelae) within 12 weeks prior to screening, or any planned surgical procedure scheduled to occur during the study.
  • Have a clinically significant history of multiple or severe allergies or an anaphylactic reaction to prescription or nonprescription drugs or food.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Cohort 1 IV

    Participants will receive LY3839056 Intravenously

    Drug: LY3839056 IV

  • Experimental
    Cohort 2 IV

    Participants will receive LY3839056 Intravenously

    Drug: LY3839056 IV

  • Experimental
    Cohort 3 IV

    Participants will receive LY3839056 Intravenously

    Drug: LY3839056 IV

  • Experimental
    Cohort 4a IV

    Participants will receive LY3839056 Intravenously

    Drug: LY3839056 IV

  • Experimental
    Cohort 4b SC

    Participants will receive LY3839056 Subcutaneously

    Drug: LY3839056 SC

  • Experimental
    Cohort 5 IV

    Participants will receive LY3839056 Intravenously

    Drug: LY3839056 IV

  • Experimental
    Cohort 6a IV

    Participants will receive LY3839056 Intravenously

    Drug: LY3839056 IV

  • Experimental
    Cohort 6b SC

    Participants will receive LY3839056 Subcutaneously

    Drug: LY3839056 SC

  • Placebo comparator
    Placebo IV

    Participants will receive Placebo Intravenously

    Drug: Placebo IV

  • Placebo comparator
    Placebo SC

    Participants will receive Placebo Subcutaneously

    Drug: Placebo SC

Interventions

  • DrugLY3839056 IV

    LY3839056 Administered Intravenously

    Also known as: LY3839056 Administered IV

  • DrugPlacebo IV

    Placebo Administered Intravenously

    Also known as: Placebo Administered IV

  • DrugLY3839056 SC

    LY3839056 Administered Subcutaneously

    Also known as: LY3839056 Administered SC

  • DrugPlacebo SC

    Placebo Administered Subcutaneously

    Also known as: Placebo Administered SC

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of LY3839056 following single-dose administration (IV or SC) in healthy participants.

    Frequency of AEs, TEAEs, SAEs, and Discontinuation due to TEAEs.

    Time frame: Baseline through Day 85

Secondary outcomes

  1. PK: Cmax

    Maximum Observed Concentration (Cmax) of LY3839056 following single SC or IV dose

    Time frame: Predose on Day 1 up to Day 85

  2. PK: AUC

    Area Under the Concentration Versus Time Curve (AUC) of LY3839056 following single SC or IV dose

    Time frame: Predose on Day 1 up to Day 85

  3. PK: t1/2

    Half Life (t1/2) of LY3839056 following single SC or IV dose

    Time frame: Predose on Day 1 up to Day 85

  4. PK: F%

    Bioavailability (F%) of LY3839056 following single SC dose

    Time frame: Predose on Day 1 up to Day 85

07

Study locations

1 site
  • Huashan Hospital, Fudan University (复旦大学附属华山医院) 12 Urumqi Middle Road
    Shanghai, Shanghai Municipality 200040, China
    • Xiaojie Wu, PhD · Contact13524686330
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 18, 2026
StartEst.
Dec 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07945314
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@lilly.com
1-317-615-4559
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion